menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Fermion Tech & Simcere Enter into Agreement for China`s 1st SSTR4 Agonist

    PR NEWSWIRE

    Fermion, Simcere Collaborate On China`s 1st SSTR4 Agonist For Pain

    PR NEWSWIRE

    AbbVie pens $1B deal for Simcere’s phase 1 T-cell engager

    PRESS RELEASE

    China Approves Simcere`s Sanbexin® For Acute Ischemic Stroke

    PR NEWSWIRE

    World Stroke Congress: TASTE-2 Reduces Stroke Disability

    PR NEWSWIRE

    Sanbexin® Significantly Reduces Stroke Disability at TASTE-2

    PR NEWSWIRE

    Sanbexin Sublingual Tablets Granted Breakthrough Therapy Status By FDA

    PR NEWSWIRE

    Connect Biopharma Reports First Half 2024 Financial Results

    GLOBENEWSWIRE

    Sanbexin Sublingual Tablets Receive FDA Breakthrough Therapy Designation

    PR NEWSWIRE

    Simcere Zaiming, TargetRx Enter Collaboration Agreement Focused on TGRX-326

    CONTRACT PHARMA

    Simcere Zaiming Partners With TargetRx On Third-Generation ALK Inhibitor

    PR NEWSWIRE

    Simcere and Connect Enter into license and collaboration agreement

    PR NEWSWIRE

    California biotech Connects with Simcere in $141M licensing pact

    FIERCE BIOTECH

    Simcere Announces Agreement with Boston-based Mass General Brigham

    BUSINESSWIRE

    Simcere is on the Fast Track Toward Building an Global Pharmaceutical Company

    PR NEWSWIRE

    Simcere Zaiming Announces Clinical Collaboration to Evaluate SIM0235

    PR NEWSWIRE

    First Prescription for COSELA® (trilaciclib) Issued in China

    PR NEWSWIRE

    China approves two domestically developed COVID drugs

    REUTERS

    Ascletis Announces Entering into a Agreement of Ritonavir Tablets with Simcere

    PR NEWSWIRE

    PHASE II/III CLINICAL TRIAL OF SIMCERE`S 3CL-TARGETING ANTI-SARS-COV-2 DRUG

    PR NEWSWIRE

    For $30M, Simcere picks up regional rights to Idorsia’s insomnia drug

    ENDPTS

    Idorsia and Simcere enter into a licensing agreement for daridorexant in China

    GLOBENEWSWIRE

    Simcere and Idorsia enter into a licensing agreement for daridorexant in China

    PRNEWSWIRE

    Simcere Receives FDA Clearance of IND for Bi-functional Fusion Protein, SIM0237

    PRNEWSWIRE

    Almirall and Simcere enter into a licensing agreement for IL-2-mu-Fc

    PRESS RELEASE

    Simcere Pharmaceutical Announces Financial Results for 2022 H1

    PRNEWSWIRE

    Tamas Oravecz named SVP, CSO of the U.S. of Simcere Pharmaceutical Group

    PRNEWSWIRE

    SIMCERE PHARMA`s 3CLpro SIM0417 Received Second Clinical Trial Approval in China

    PRNEWSWIRE

    Proprietary SARS-CoV-2 3CL Inhibitor Rapidly Progressing in Clinical Trials

    PRNEWSWIRE

    Primary endpoint met in Phase III trial of Trilaciclib in Chinese patients

    PRNEWSWIRE

    Simcere Pharma (2096.HK) Announces a Positive Profit Alert

    PRNEWSWIRE

    Bijoyesh Mookerjee Appoints CMO, Oncology for Simcere Pharmaceuticals

    PRNEWSWIRE

    Aeromics, Simcere Begins First-In-Human Dosing in Phase I of SIM0307 (AER-271)

    PRNEWSWIRE

    Simcere, SIMM Collaborate for Next-Gen COVID-19 Oral Antivirals

    PRNEWSWIRE

    Alzheimer`s gold rush inspires $565M deal between Chinese pharma powerhouse

    ENDPTS

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.